Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850707 | 0.91 | ALDH1A1 (0.74) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL29550875 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL532500 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL7341640 | 0.86 | ALDH1A1 (0.71) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL4289121 | 0.84 | ALDH1A1 (0.71) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL10652999 | 0.83 | MAPT (0.78) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL4291442 | 0.83 | ALDH1A1 (0.75) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL4264178 | 0.83 | ALDH1A1 (0.75) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL4861393 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPTRXFP1PKMKDM4E | |
| SCHEMBL27593103 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPTRXFP1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | ALDH1A1 313/4885MAPT 2057/4885RXFP1 312/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | ALDH1A1 736/4885MAPT 1924/4885RXFP1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.